Financial Performance - The company reported net product sales of $184 million for Q2 2024 from its COVID-19 vaccine, a decrease from $293 million in Q2 2023[107]. - Total revenue for Q2 2024 was $241 million, a decrease of 30% compared to $344 million in Q2 2023[117]. - Net product sales in Q2 2024 were $184 million, down 37% from $293 million in Q2 2023[117]. - Net loss for Q2 2024 was $1.279 billion, a slight improvement of 7% from a net loss of $1.380 billion in Q2 2023[117]. - Total revenue for the first half of 2024 was $408 million, an 82% decrease from $2.206 billion in the first half of 2023[117]. - Net product sales for the first half of 2024 were $351 million, down 83% from $2.121 billion in the first half of 2023[117]. - The company reported a net loss of $2.5 billion for the six months ended June 30, 2024, compared to a net loss of $4.7 billion for the year ended 2023[147]. Research and Development - The company has a diverse pipeline with 40 development candidates across 47 programs, with 43 currently in clinical studies[99]. - The FDA approved mRESVIA (mRNA-1345) for adults aged 60 and older, showing a vaccine efficacy of 83.7% against RSV lower respiratory tract disease in a Phase 3 trial involving approximately 37,000 adults[103]. - The next-generation COVID-19 vaccine candidate (mRNA-1283) demonstrated non-inferior efficacy compared to Spikevax in a Phase 3 trial for participants aged 12 and older[108]. - A combination vaccine candidate against influenza and COVID-19 (mRNA-1083) showed higher immune responses than licensed vaccines in adults aged 50 and older[110]. - The investigational therapy for Methylmalonic Acidemia (mRNA-3705) was selected for the FDA's START pilot program to expedite development for rare diseases[113]. - The company is actively enrolling in Phase 3 trials for mRNA-4157 (V940) in combination with KEYTRUDA for high-risk melanoma and non-small cell lung cancer[112]. Sales and Market Activity - The company commenced sales of its COVID-19 vaccine to the U.S. commercial market in Q3 2023, expanding its sales channels[120]. - The U.S. COVID-19 vaccine sales are primarily to wholesalers and distributors, with some sales to retailers and healthcare providers[120]. - Net product sales for the three and six months ended June 30, 2024, decreased by $109 million (37%) and $1.8 billion (83%), respectively, compared to the same periods in 2023, primarily due to lower sales volumes and the transition to a seasonal commercial pattern for the COVID-19 vaccine market[124]. Expenses and Cash Flow - Operating expenses for Q2 2024 totaled $1.604 billion, a reduction of 27% from $2.211 billion in Q2 2023[117]. - Research and development expenses increased by 6% to $1.221 billion in Q2 2024, compared to $1.148 billion in Q2 2023[117]. - Selling, general and administrative expenses decreased by $64 million (19%) for the three months ended June 30, 2024, compared to the same period in 2023, mainly due to reduced consulting and outside services[131]. - Cash, cash equivalents, and investments as of June 30, 2024, decreased by $2.5 billion (19%) compared to December 31, 2023, primarily due to a net cash outflow from operating activities[138]. - Net cash used in operating activities for the six months ended June 30, 2024 was $2.3 billion, an increase of $123 million, or 6%, compared to the same period in 2023[143][144]. - Net cash provided by investing activities was $1.8 billion, primarily from proceeds of $5.5 billion from maturities and sales of marketable securities[145]. - Net cash provided by financing activities increased by $1.3 billion, or 104%, to $48 million for the six months ended June 30, 2024[146]. Deferred Revenue and Taxation - Deferred revenue as of June 30, 2024, was $740 million, primarily associated with customer deposits for COVID-19 vaccine deliveries scheduled in 2024[122]. - The provision for income taxes increased by $369 million (100%) and $763 million (101%) for the three and six months ended June 30, 2024, compared to the same periods in 2023, due to taxable income from foreign subsidiaries[136]. - Deferred revenue related to customer deposits received or billable was $740 million as of June 30, 2024[142]. Future Outlook - The company anticipates significant future capital requirements for ongoing research and development activities, including new vaccine candidates and manufacturing costs[148]. - Cash, cash equivalents, and investments as of June 30, 2024, are expected to be sufficient to fund projected operations and capital expenditures for at least the next 12 months[149]. - The company experienced a decline in customer demand for its COVID-19 vaccine in 2023, continuing into the first half of 2024[149].

Second Quarter 2024 Financial Results August 1, 2024 mode © 2024 Moderna, Inc. All rights reserved. Forward-looking statements and disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's expected product sales in 2024 and trends informing Moderna's 2024 sales outlook; Moderna's ability to meet the 2024/2025 respiratory virus season demand and to drive vaccination rates; ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Moderna (MRNA) came out with a quarterly loss of $3.33 per share versus the Zacks Consensus Estimate of a loss of $3.47. This compares to loss of $3.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 4.03%. A quarter ago, it was expected that this biotechnology company would post a loss of $3.59 per share when it actually produced a loss of $3.07, delivering a surprise of 14.48%. Over the last four quarters, the company has s ...

Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights. The consensus estimate for 'Revenue- Product sales' stands at $102.49 million. The estimate indicates ...

Moderna (MRNA) will report second-quarter earnings on Aug 1, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $124.9 million and a loss of $3.47 per share, respectively. Both metrics indicate significant declines from the year-ago quarter's levels. MRNA's loss estimates have remained consistent at $7.46 per share for 2024 and $5.29 for 2025 in the past 30 days. | --- | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------|--- ...

MRNA Stock Outperforms Industry, Sector & S&P 500 Encouraging Upcoming Launches Moderna (MRNA) has risen 22.1% in the year-to-date period against the industry's 2.7% fall, as seen in the chart below. The stock also outperformed the sector and the S&P 500. Shares of the company are currently trading above its 200-day moving average. Image Source: Zacks Investment Research Despite registering a significant fall in top-line due to lower COVID-19 vaccine sales, Moderna's shares continue to soar this year on the ...

Discounted stock prices make these strong brands worth considering as investments. Let's take a look at two stocks that trade down significantly from recent highs and see why they might be good stocks to buy right now. Smart investors see that disparity and know it means there are some discounted stocks to be found. The trick, of course, is discerning which of the discounted stocks represent quality companies experiencing a short-term issue (or issues). Not every stock that falls is a wise investment. Howev ...

Group 1: Healthcare Sector Outlook - The outlook for many healthcare stocks is positive, partly due to large investors avoiding the sector, believing it will yield poor returns as long as interest rates remain high [1] Group 2: Walgreens Boots Alliance (WBA) - Walgreens is facing tough competition from large retail chains like Walmart and Target, and increased use of direct mail prescription services has negatively impacted its earnings, which fell to 63 cents per share from 99 cents year-over-year [3] - Analysts predict Walgreens' earnings per share will decline to $2.79 in 2025 from $3.98 in 2023 [4] - The company has significant challenges, including high settlements related to the opioid crisis, resulting in a debt of $33.66 billion and only $711 million in cash as of the end of Q1 [10] - Increased shoplifting and inflation have further hurt Walgreens' financial results, making consumers less willing to pay high prices compared to competitors [19] Group 3: Cassava Sciences (SAVA) - Cassava's only major drug candidate, simufilam, is under scrutiny after Professor Hoau-Yan Wang was indicted for allegedly falsifying data, which could jeopardize the drug's Phase 3 trials [5][11] - If the FDA finds that Cassava knowingly submitted false data, it could lead to severe consequences for the company and a significant drop in its stock price [6][11] - Cassava has been accused of manipulating clinical trial results, raising concerns about the drug's efficacy [12][22] Group 4: Moderna (MRNA) - Moderna's revenue from its Covid-19 vaccine dropped significantly by two-thirds to $6.7 billion last year, as public concern about the virus decreased [14] - Analysts expect Moderna's revenue to decline to $3.85 billion this year from $6.85 billion in 2023 [15] - Moderna's RSV vaccine efficacy is reported at 50% after 18 months, which is less impressive compared to GSK's vaccine that was approved earlier [24]

Core Insights - Moderna announced a $176 million federal grant to develop a bird flu vaccine for humans, focusing on the H5 influenza virus which poses a significant risk to both birds and humans [1][2] - The grant is part of the Rapid Response Partnership Vehicle (RRPV) from the U.S. Department of Health and Human Services, aimed at accelerating mRNA-based vaccine development [2] - Moderna has initiated a Phase 1/2 trial for the H5 influenza vaccine in 2023, with results expected this year to inform further development plans [3][6] Financial Impact - Following the announcement of the federal grant, Moderna's shares increased by 0.5% to $116.54, marking a 17% rise in share value so far in 2024 [4][7] Public Health Context - The CDC reported four human cases of bird flu since 2022, with the WHO documenting 254 cases globally since January 2023, highlighting the ongoing public health concern [5]